A ray of sunshine has appeared for medical device developers seeking to market their devices in the US as well as other territories.
Often, manufacturers wrestle with ensuring that their development process, activities and documentation aligns with both ISO 13485 and the Quality System Regulation (21 CFR 820).
US FDA has announced plans to harmonise the requirements contained in 21 CFR 820 with the content of ISO 13485:2016. There is planned to be a fundamental revision to part 820, that will “supplant the existing requirements” with the content of the revised 13485 standard. The agency intends the changes to reduce the compliance and record keeping burdens on manufacturers.
For the canny development organisation, little will actually change, as they will have planned their activities to achieve compliance with both the US and other territories requirements at the same time. FDAs intentions will make their lives a little easier, removing the need for translations between, for example document names, from the standard and part 820 terminologies.
For people embarking upon development with an eye on the US market for the first time, there’s likely to be one less hurdle to surmount once FDA’s intentions bear fruit.
Ultimately, the plans are good news for manufacturers who develop and market products for the EU, Japan, Canada, Australia (and the US), as all have regulatory requirements aligned with a single Quality Management Standard – leading to a reduction in compliance requirements for manufacturer Quality Management systems.
You may be thinking about seeking reassurance that your medical device development plans adequately address the regulatory requirements of the US and ISO 13485:2016 aligned regulations. Get in touch with our team today.